

Exploring the Genetic Link Between Thyroid Dysfunction and Common Psychiatric Disorders: a Specific Hormonal, or a General Autoimmune Comorbidity

Sourena Soheili-Nezhad¹

Emma Sprooten¹

Indira Tendolkar²

Marco Medici^{3,4,5}

¹Department of Cognitive Neuroscience, Donders Institute for Brain, Cognition, and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands

²Department of Psychiatry, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Centre, Nijmegen, the Netherlands

³Academic Center for Thyroid Diseases, Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands

⁴Department of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands

⁵Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Centre, Nijmegen, the Netherlands

Correspondence to Marco Medici, MD, PhD, MSc, Academic Center for Thyroid Diseases, Department of Internal Medicine and Department of Epidemiology, Erasmus Medical Center, Dr. Molewaterplein 50, 3015 GE, Rotterdam, the Netherlands. email: m.medic@erasmusmc.nl

This work was supported by funding from the Radboud University (Healthy Brain Study pre-seed grant).

Abstract

Background: The hypothalamus-pituitary-thyroid axis coordinates brain development and post-developmental function. Thyroid hormone variations, even within the normal range, have been associated with the risk of developing common psychiatric disorders, although the underlying mechanisms remain poorly understood.

Materials and methods: To get new insight into the potentially shared mechanisms underlying thyroid dysfunction and psychiatric disorders, we performed a comprehensive analysis of multiple phenotypic and genotypic databases. We investigated the relationship of thyroid disorders with depression, bipolar disorder, and anxiety disorders in 502,480 subjects from UK Biobank. We subsequently investigated genetic correlations between thyroid disorders, thyroid stimulating hormone (TSH) and free T4 (FT4) levels, with the genome-wide factors that predispose to psychiatric disorders. Finally, the observed global genetic correlations were furthermore pinpointed to specific local genomic regions.

Results: Hypothyroidism was positively associated with an increased risk of major depressive disorder (OR=1.51, $p < 10^{-16}$) and bipolar disorder (OR=1.99, $p = 2.1 \times 10^{-6}$). Genetically, strong coheritability was observed between autoimmune hypothyroidism and both major depressive ($r_g = 0.17$, $p = 2.7 \times 10^{-4}$) and anxiety disorders ($r_g = 0.17$, $p = 6.7 \times 10^{-6}$). This genetic correlation was particularly strong at the Major Histocompatibility Complex (MHC) locus on chromosome six ($p < 10^{-5}$), but further analysis showed that other parts of the genome also contributed to this global effect. Importantly, neither TSH nor FT4 levels were genetically correlated with mood disorders.

Conclusion: Our findings highlight an underlying association between autoimmune hypothyroidism and mood disorders, which is not mediated via thyroid hormones, and in which autoimmunity plays a prominent role. While these findings could shed new light on the potential ineffectiveness of treating (minor) variations in thyroid function in psychiatric disorders, further research is needed to identify the exact underlying molecular mechanisms.

Introduction

Thyroid hormone (TH) plays a key role in brain development and neurocognitive function [1, 2]. Both hypo- and hyperthyroidism have been associated with an increased risk of various psychiatric diseases [3], including depression, bipolar and anxiety disorders [4]. More recently, it has even been shown that minor subclinical variations in thyroid function, even within the normal range, are associated with these psychiatric diseases [5, 6], although some studies report contradicting findings [7, 8]. A better understanding of the biological processes underlying these associations could have highly valuable implications for both clinical psychiatry and endocrinology.

The most common forms of thyroid dysfunction have an autoimmune origin and there is increasing evidence that the immune system and inflammatory response are also relevant for the pathophysiology of psychiatric disorders [9, 10]. Next to the direct effects of TH on brain, the effects of thyroid dysfunction on psychiatric diseases could thus be mediated by more generally associated autoimmune processes [11]. Various cellular mechanisms have been proposed for this phenomenon, ranging from binding of thyroid peroxidase antibodies (TPOabs) to human

astrocytes, coinciding anti-central nervous system auto-antibodies in thyroid diseases, to increased production of monocyte- and T-lymphocyte derived cytokines [11]. *Vice versa*, psychiatric disorders have also been shown to be associated with abnormalities in thyroid function tests [12, 13]. These include mild elevations as well as decreases in thyroid hormone levels, blunting of the TSH response to TRH stimulation, and absence of the nocturnal surge of TSH. In addition, psychiatric disorders have also been suggested to be associated to altered autoimmune processes [14].

Taken together, there is still a large knowledge gap whether the observed associations between (minor or overt) thyroid abnormalities and psychiatric diseases are directly mediated via TH or not. This is a clinically relevant gap, as understanding the complex interactions between thyroid status, autoimmunity, and psychiatric disorders is a prerequisite before making treatment recommendations to prevent or treat coinciding psychiatric disorders in a patient with mild thyroid dysfunction, or vice versa.

In the context of these complex interactions, it is noteworthy that an estimated 60-70% of the inter-individual variation in thyroid function is determined by genetic factors [15]. Next to a direct genetic relationship between thyroid function and psychiatric disorders, various studies have suggested that genetic factors play an important role in various other autoimmune diseases as well as psychiatric disorders [16-18]. In recent years, genome-wide association studies (GWAS) have been particularly successful in identifying the genetic determinants of thyroid function [19, 20], and more recently of psychiatric disorders [21]. With the availability of these data, this is the optimal moment to investigate the role of common genetic variants in the complex relations between thyroid function, autoimmunity and common psychiatric diseases.

Doing so could help understand whether the well-known clinical comorbidity between thyroid diseases and psychiatric disorders is specifically driven by thyroid hormones, or has a more general autoimmune-related basis. Therefore, in the current study, we tested phenotypic and genetic correlations in large datasets of thyroid diseases, thyroid hormone levels, and three common psychiatric disorders coinciding with thyroid dysfunction, i.e., major depressive disorder, bipolar disorder and anxiety disorder.

Methods

Phenotypic correlation

We studied the co-occurrence of thyroid dysfunction and psychiatric disorders in 502,480 subjects of UK biobank. The clinical diagnosis of hyperthyroidism or hypothyroidism was recorded as International Classification of Diseases (ICD-10) codes (table S1). Subjects with the history of both hypo- and hyperthyroidism were removed from the analysis ($n=1,178$). In the current work, we considered three common psychiatric disorders, including major depressive disorder (MDD), bipolar disorder (BIP) and anxiety disorder (ANX). These phenotypes were extracted from various data fields and questionnaires similar to previous studies (table S2). The statistical association of thyroid disease with each of the three psychiatric disorders was assessed using logistic regression while controlling for the confounding effects of sex, age, age², and the interactions between sex×age and sex×age².

Global genetic correlation

The genetic correlations of TSH and FT4 and thyroid diseases with ANX, MDD and BIP were estimated using LD-score regression (<https://github.com/bulik/ldsc> [22, 23]) and the largest GWAS summary statistics available for each phenotype at the date of analysis: the GWAS of TSH and FT4 levels within the normal range [24], TSH in the entire range [25] (i.e., including unaffected subjects and subjects affected by thyroid disease), a recent GWAS of auto-immune thyroid disorders [26], bipolar disorder [27], anxiety disorder [28] and major depressive disorder [29] as available at the psychiatric genomics consortium portal (<https://www.med.unc.edu/pgc> [30]). GWAS data were filtered using minor allele frequency >0.01 and an imputation info score cut-off of 0.9. The GWASs of multiple phenotypes in UK biobank have been previously performed by Neale lab and generously released for third-party use. This dataset includes the GWAS of thousands of phenotypes related to lifestyle, general health and medical history conditions (https://github.com/Nealelab/UK_Biobank_GWAS). We retrieved the SNP summary statistics of self-reported Hypothyroidism and Hypothyroidism phenotypes from this repository (table 1).

Local genetic correlation

For those phenotype pairs demonstrating significant global genetic correlations, we subsequently tested their local genetic correlation using Local Analysis of Variant Annotation (LAVA [31]). This procedure divides the genome into 2,495 local linkage disequilibrium (LD) blocks and then estimates genetic correlations within each LD block.

After identifying LD blocks of strong genetic correlation using LAVA, these “hotspots” were removed from the global genetic correlation analyses, to estimate the remaining genetic

correlation excluding the local hotspots. This analysis was aimed at understanding whether the coheritability of thyroid disease and psychiatric disorders was driven by a small number of strong local genetic correlations or was rather distributed at many loci across the genome.

Results

Phenotypic correlations

First, we verified associations between thyroid dysfunction, mood and anxiety disorders in a large population-based cohort (UK Biobank), the results of which are shown in Table 2. The most common mood disorder was major depressive disorder (broad definition [29], with a prevalence of 35.1% in the cohort), followed by anxiety disorder (5.3%) and bipolar disorder (0.2%). The prevalences of hypothyroidism and hyperthyroidism were 3.8% and 0.3%, respectively.

Hypothyroidism was positively associated with an increased risk of major depressive disorder and bipolar disorder, while hyperthyroidism was associated with an increased risk of major depressive disorder (table 2). The association of hypothyroidism with bipolar disorder was particularly strong (OR=1.99). No significant phenotypic correlations were observed between either thyroid disease and anxiety disorder.

Global genetic correlations

Next, we investigated global genetic correlations between thyroid traits and mood and anxiety disorders, the results of which are shown in Table 3, along with the observed SNP-heritability estimates (h^2 -SNP). Among the traits, hyperthyroidism had very low SNP heritability (0.006), and was therefore not included in subsequent analyses.

We observed strong genetic correlations between autoimmune thyroid diseases and major depressive disorder ($r_g=0.13$, $p=2.7\times 10^{-4}$) and anxiety disorder ($r_g=0.16$, $p=6.7\times 10^{-6}$), but not with bipolar disorder. As autoimmune thyroid diseases include both autoimmune hypothyroidism as well as Graves' disease, the results were validated using an independent GWAS on hypothyroidism in UK biobank (table 3), concluding that the observed associations were predominantly driven by autoimmune hypothyroidism.

Next, to explore whether the observed genetic correlations with hypothyroidism are driven by thyroid hormone levels or autoimmunity (i.e., independently of thyroid hormone levels), genetic correlations between thyroid hormone levels, mood and anxiety disorders were tested. Despite higher SNP-heritability estimates for TSH and FT4, there were no significant genetic correlations between TSH or FT4, either in the normal or the entire range, and any of the mood and anxiety disorders.

Local genetic correlation

Finally, we carried out local genetic correlation analyses to refine the genomic regions underlying the observed global genetic correlations between hypothyroidism, mood and anxiety disorders. A strong local genetic correlation block was observed between autoimmune thyroid disease, anxiety and major depressive disorders at loci 6p22.1 and 6p22.2 (table 4 and 5), flanking the major histocompatibility complex (MHC) region. Another such "hotspot" of local genetic correlation was identified in chromosome 12, in a region containing multiple genes (RAP1B, NUP107, SLC35E3, MDM2, CPM, CPSF6, LYZ, YEATS4, FRS2, CCT2, LRRC10, BEST3; table 4 and 5).

Contrary to our expectation, after excluding these “hotspots” of local genetic correlation, the calculated global genetic correlation remained high (anxiety disorder $p=4.2 \times 10^{-6}$ and major depressive disorder $p=2.7 \times 10^{-4}$), indicating that the observed genetic correlations are spread across the genome rather than localized to a few hotspots.

Discussion

In the current study, we systematically analyzed the role of common genetic variants in the complex relations between thyroid function, autoimmunity and three common psychiatric disorders. We found strong genetic correlations between autoimmune hypothyroidism, major depressive disorder and anxiety disorders. Despite higher SNP-heritability estimates for thyroid function (TSH and FT4), there were no significant genetic correlations between TSH and FT4 and any of these psychiatric disorders. This may suggest that the genetically determined relation between hypothyroidism and mood/anxiety disorders is not mediated via thyroid hormones directly, but via pathways that underpin disease pathogenesis, such as (general) autoimmunity. This was further supported by our regional genetic correlation analyses, in which the top locus was the MHC region, which plays a central role in the pathogenesis of various autoimmune disorders, including autoimmune hypothyroidism [32]. It has been known for long that inflammatory pathways play a central role in the pathogenesis of autoimmune hypothyroidism. However, in the last decade various studies have shown that inflammatory pathways also play a key role in the pathogenesis of many psychiatric disorders [33-35]. Notably, studies on inflammatory biomarkers have been unable to detect markers that are specific for any particular

psychiatric disorder, thereby suggesting genetic variation in autoimmunity to be a more general underlying phenomenon. Various biological treatment regimes, including pharmacotherapy and non-invasive brain stimulation with electroconvulsive therapy (ECT) indeed lead to a reduction of pro-inflammatory markers, highlighting the role of inflammation in psychiatric vulnerability [36, 37]. Next to inflammatory pathways leading to both autoimmune hypothyroidism and increased psychiatric vulnerability, coinciding autoimmune disorders might also for other reasons than shared inflammatory pathways be responsible for the observed relations between thyroid and psychiatric disorders. Indeed, it has been shown that autoimmune hypothyroidism coincides with several other autoimmune conditions, such as rheumatoid arthritis, celiac disease, type 1 diabetes, premature ovarian failure and adrenal insufficiency [38]. These comorbidities have also been associated with various psychiatric diseases, including MDD and anxiety disorders. Therefore, future studies in well-phenotyped cohorts should assess which part of the observed associations between hypothyroidism and psychiatric disorders is actually driven by these other autoimmune comorbidities. Furthermore, one of the several mechanistic hypotheses underlying the coincidence of multiple autoimmune conditions is that various tissues share the same epitopes, to which autoantibodies can cross-react [39]. In this context, Benveniste et al. [40] recently showed an interesting amino acid sequence homology between thyroid autoantigens and central nervous system proteins, including thyroid peroxidase, autoantibodies to which are a characteristic biomarker for Hashimoto's hypothyroidism.

Irrespective of the exact underlying mechanisms, our findings have also clinical relevance. Based on the well-known clinical correlations, thyroid dysfunction is among the first somatic disorders to be ruled out in a patient with a newly diagnosed psychiatric disorder. Various studies have

investigated whether correction of milder forms of thyroid dysfunction (including subclinical hypothyroidism) improves depressive and anxiety-related symptoms, with disappointing results [41, 42]. Our finding that the genetically determined relation between hypothyroidism and mood/anxiety disorders is not mediated via thyroid hormones, but more likely by (general) autoimmunity, is a plausible explanation for this lack of effects, and supports a restrictive attitude towards treating mild thyroid dysfunction in psychiatric patients.

Besides psychiatric disorders, milder affective and anxiety related complaints are frequently reported in hypothyroid patients. Unfortunately, these complaints persist in 10-15% of levothyroxine treated patients despite normalization of their thyroid hormone levels, which is among the largest knowledge gaps in endocrinology [43]. Our findings suggest that the psychiatric vulnerability in Hashimoto's hypothyroidism patients is at least partly mediated via autoimmunity and not thyroid function, which would be a plausible explanation as to why these patients have persisting complaints despite the normalization of their thyroid hormone levels.

Our combined phenotypic and genetic analyses across multiple psychiatric and thyroid traits allowed us to better understand their shared biological underpinnings, more so than we would have in a purely phenotypic analysis. While our evidence for genetic overlap strongly encourages further research into shared molecular mechanisms, the approaches we used remain observational and do not directly exclude alternative causal explanations. For example, heritable lifestyle factors (such as diet and physical activity) are shared predisposing factors to both psychiatric disorders and thyroid diseases, so these could be contributing mediating factors in addition to any directly mediating, purely molecular inflammation pathways [44-48]. Future

research using mendelian randomisation [49] and longitudinal designs are warranted to better inform on the different possible causal mechanisms.

Our local genetic correlation analysis identified two loci as potential mediators of the genetic overlap between thyroid and mood/anxiety disorders. Notably, one of these two regions maps to 6p22.1. Common variants in this region have been previously implicated in schizophrenia [50]. This locus flanks the major histocompatibility complex (MHC) genes and is a genetic correlation 'hub' across multiple, mostly (auto)immune-related clinical conditions [31].

Our genetic analysis was made possible by the recent surge in well powered GWAS data from very large sample sizes and consortia, both in psychiatry and endocrinology. The resultant power, and the fact that our genetic correlations are based on independent samples, strengthen the present study. However, a limitation of using existing GWAS statistics is that they differ in statistical power, and consequently the genetic correlations are not directly comparable across traits. Despite being based on larger sample sizes than the autoimmune hypothyroidism analyses, no genetic correlation was found between TSH/FT4 and psychiatric disorders. This strengthens the finding that the observed association between autoimmune hypothyroidism and psychiatric disorders is for an important part autoimmune related.

It is difficult to know whether the strong phenotypic correlation we found between bipolar disorder and hypothyroidism is not driven by genetic variation at all, or whether it is due to lower statistical power in the bipolar disorder GWAS data we used. Nevertheless, GWAS data for major depressive disorder and schizophrenia were very well powered, and provided robust results that were consistent across two independent GWASs of thyroid disease. Similarly,

differences in prevalence across the different diseases is a limitation of the phenotypic correlation analysis, especially in a population-based sample like UK Biobank. Especially for hyperthyroidism, this limits the conclusions we can draw. In contrast, the higher prevalence for hypothyroidism and major depression led to well powered phenotypic correlation analyses and conclusive results.

In conclusion, our results indicate that autoimmunity rather than thyroid hormone itself plays a key role in the genetically determined relations between hypothyroidism and mood/anxiety disorders. Next to providing valuable clinical insights into the potential benefits of treating milder forms of thyroid dysfunction, these findings warrant further research into the autoimmune mechanisms underpinning these common coexisting diseases that may lead to a shift in personalizing treatment in the future.

References

1. Bernal, J., *Thyroid hormone receptors in brain development and function*. Nature clinical practice Endocrinology & metabolism, 2007. **3**(3): p. 249-259.
2. Prezioso, G., C. Giannini, and F. Chiarelli, *Effect of thyroid hormones on neurons and neurodevelopment*. Hormone research in paediatrics, 2018. **90**(2): p. 73-81.
3. Pompili, M., et al., *Prolactin and thyroid hormone levels are associated with suicide attempts in psychiatric patients*. Psychiatry research, 2012. **200**(2-3): p. 389-394.
4. Bauer, M., et al., *The thyroid-brain interaction in thyroid disorders and mood disorders*. Journal of neuroendocrinology, 2008. **20**(10): p. 1101-1114.
5. Williams, M., et al., *Thyroid function and the natural history of depression: findings from the Caerphilly Prospective Study (CaPS) and a meta-analysis*. Clinical endocrinology, 2009. **70**(3): p. 484-492.
6. Medici, M., et al., *Thyroid function within the normal range and the risk of depression: a population-based cohort study*. The Journal of Clinical Endocrinology & Metabolism, 2014. **99**(4): p. 1213-1219.
7. Bode, H., et al., *Association of Hypothyroidism and Clinical Depression: A Systematic Review and Meta-analysis*. JAMA psychiatry, 2021. **78**(12): p. 1375-1383.
8. Wildisen, L., et al., *An individual participant data analysis of prospective cohort studies on the association between subclinical thyroid dysfunction and depressive symptoms*. Scientific reports, 2020. **10**(1): p. 1-12.
9. Rudzki, L. and M. Maes, *The Microbiota-Gut-Immune-Glia (MGIG) Axis in Major Depression*. Mol Neurobiol, 2020. **57**(10): p. 4269-4295.
10. Benros, M.E., W.W. Eaton, and P.B. Mortensen, *The epidemiologic evidence linking autoimmune diseases and psychosis*. Biol Psychiatry, 2014. **75**(4): p. 300-6.
11. Leyhe, T. and K. Müssig, *Cognitive and affective dysfunctions in autoimmune thyroiditis*. Brain Behav Immun, 2014. **41**: p. 261-6.
12. Fischer, S. and U. Ehlert, *Hypothalamic-pituitary-thyroid (HPT) axis functioning in anxiety disorders. A systematic review*. Depress Anxiety, 2018. **35**(1): p. 98-110.
13. Premachandra, B.N., M.A. Kabir, and I.K. Williams, *Low T3 syndrome in psychiatric depression*. J Endocrinol Invest, 2006. **29**(6): p. 568-72.
14. Karakatsoulis, G.N., et al., *Subclinical thyroid dysfunction and major depressive disorder*. Hormones, 2021. **20**(4): p. 613-621.
15. Hansen, P.S., et al., *Major genetic influence on the regulation of the pituitary-thyroid axis: a study of healthy Danish twins*. The Journal of Clinical Endocrinology & Metabolism, 2004. **89**(3): p. 1181-1187.
16. Grotzinger, A.D., *Shared genetic architecture across psychiatric disorders*. Psychological Medicine, 2021. **51**(13): p. 2210-2216.
17. Gordovez, F.J.A. and F.J. McMahon, *The genetics of bipolar disorder*. Molecular psychiatry, 2020. **25**(3): p. 544-559.
18. McIntosh, A.M., P.F. Sullivan, and C.M. Lewis, *Uncovering the genetic architecture of major depression*. Neuron, 2019. **102**(1): p. 91-103.
19. Teumer, A., et al., *Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulation*. Nature communications, 2018. **9**(1): p. 1-14.
20. Zhou, W., et al., *GWAS of thyroid stimulating hormone highlights pleiotropic effects and inverse association with thyroid cancer*. Nature communications, 2020. **11**(1): p. 1-13.
21. *Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders*. Cell, 2019. **179**(7): p. 1469-1482.e11.

22. Bulik-Sullivan, B.K., et al., *LD Score regression distinguishes confounding from polygenicity in genome-wide association studies*. Nature Genetics, 2015. **47**(3): p. 291-295.
23. Bulik-Sullivan, B., et al., *An atlas of genetic correlations across human diseases and traits*. Nature Genetics, 2015. **47**(11): p. 1236-1241.
24. Teumer, A., et al., *Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulation*. Nature communications, 2018. **9**(1): p. 4455-4455.
25. Zhou, W., et al., *GWAS of thyroid stimulating hormone highlights pleiotropic effects and inverse association with thyroid cancer*. Nature Communications, 2020. **11**(1): p. 3981.
26. Saevarsdottir, S., et al., *FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease*. Nature, 2020. **584**(7822): p. 619-623.
27. Stahl, E.A., et al., *Genome-wide association study identifies 30 loci associated with bipolar disorder*. Nat Genet, 2019. **51**(5): p. 793-803.
28. Purves, K.L., et al., *A major role for common genetic variation in anxiety disorders*. Mol Psychiatry, 2020. **25**(12): p. 3292-3303.
29. Wray, N.R., et al., *Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression*. Nat Genet, 2018. **50**(5): p. 668-681.
30. Watson, H.J., Z. Yilmaz, and P.F. Sullivan, *Chapter 9 - The Psychiatric Genomics Consortium: History, development, and the future*, in *Personalized Psychiatry*, B.T. Baune, Editor. 2020, Academic Press: San Diego. p. 91-101.
31. Werme, J., et al., *An integrated framework for local genetic correlation analysis*. Nat Genet, 2022. **54**(3): p. 274-282.
32. Jacobson, E.M., A. Huber, and Y. Tomer, *The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology*. Journal of autoimmunity, 2008. **30**(1-2): p. 58-62.
33. Miller, A.H., V. Maletic, and C.L. Raison, *Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression*. Biol Psychiatry, 2009. **65**(9): p. 732-41.
34. Horváth, S. and K. Mirnics, *Immune system disturbances in schizophrenia*. Biol Psychiatry, 2014. **75**(4): p. 316-23.
35. Fineberg, A.M. and L.M. Ellman, *Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia*. Biol Psychiatry, 2013. **73**(10): p. 951-66.
36. Kohler, O., et al., *Inflammation in depression and the potential for anti-inflammatory treatment*. Current neuropharmacology, 2016. **14**(7): p. 732-742.
37. Desfossés, C.-Y., et al., *The Pattern of Change in Depressive Symptoms and Inflammatory Markers After Electroconvulsive Therapy: A Systematic Review*. The Journal of ECT, 2021. **37**(4): p. 291-297.
38. Ruggeri, R.M., et al., *Autoimmune comorbidities in Hashimoto's thyroiditis: different patterns of association in adulthood and childhood/adolescence*. Eur J Endocrinol, 2017. **176**(2): p. 133-141.
39. Shaoul, R. and A. Lerner, *Associated autoantibodies in celiac disease*. Autoimmun Rev, 2007. **6**(8): p. 559-65.
40. Benvenga, S., et al., *Amino acid sequence homology between thyroid autoantigens and central nervous system proteins: Implications for the steroid-responsive encephalopathy associated with autoimmune thyroiditis*. Journal of clinical & translational endocrinology, 2021. **26**: p. 100274.
41. Najafi, L., et al., *Depressive symptoms in patients with subclinical hypothyroidism--the effect of treatment with levothyroxine: a double-blind randomized clinical trial*. Endocr Res, 2015. **40**(3): p. 121-6.
42. Walsh, J.P., et al., *Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial*. J Clin Endocrinol Metab, 2006. **91**(7): p. 2624-30.

43. Wiersinga, W.M., *Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism*. Nat Rev Endocrinol, 2014. **10**(3): p. 164-74.
44. Avinun, R., *The E Is in the G: Gene-Environment-Trait Correlations and Findings From Genome-Wide Association Studies*. Perspect Psychol Sci, 2020. **15**(1): p. 81-89.
45. Sprooten, E., B. Franke, and C.U. Grevén, *The P-factor and its genomic and neural equivalents: an integrated perspective*. Mol Psychiatry, 2022. **27**(1): p. 38-48.
46. Plomin, R., *Genotype-environment correlation in the era of DNA*. Behav Genet, 2014. **44**(6): p. 629-38.
47. Song, R.-h., et al., *The Impact of Obesity on Thyroid Autoimmunity and Dysfunction: A Systematic Review and Meta-Analysis*. Frontiers in Immunology, 2019. **10**.
48. Rayman, M.P., *Multiple nutritional factors and thyroid disease, with particular reference to autoimmune thyroid disease*. Proc Nutr Soc, 2019. **78**(1): p. 34-44.
49. Zhu, Z., et al., *Causal associations between risk factors and common diseases inferred from GWAS summary data*. Nat Commun, 2018. **9**(1): p. 224.
50. Shi, J., et al., *Common variants on chromosome 6p22. 1 are associated with schizophrenia*. Nature, 2009. **460**(7256): p. 753-757.

Tables

Table 1. GWAS summary data used in the current work

Phenotype	Class	Sample size	Reference
TSH normal range	Continuous	72,167	[24]
FT4 normal range	Continuous	72,167	[24]
TSH whole range	Continuous	119,715	[25]
Autoimmune thyroid disease	Categorical	755,406	[26]
Hypothyroidism (self-reported)	Categorical	361,141	https://github.com/Nealelab
Hyperthyroidism (self-reported)	Categorical	361,141	https://github.com/Nealelab
Anxiety disorder	Categorical	83,566	[28]
Bipolar disorder	Categorical	51,710	[27]
Major depressive disorder	Categorical	480,359	[29]

Table 2. Phenotypic associations between thyroid dysfunction and three psychiatric disorders

	No anxiety disorder (%)	anxiety disorder (%)	Total (row-wise, %)	OR	z-score (p)
Normal thyroid function	453,223 (94.7)	25,129 (5.3)	478,352 (96.0%)		
Hypothyroidism	17,653 (94.1)	1,110 (5.9)	18,763 (3.8%)	1.05	1.50 (0.133)
Hyperthyroidism	1,309 (93.3)	94 (6.7)	1,403 (0.3%)	1.17	1.50 (0.134)
Total (column-wise)	472,185 (94.7)	26,333 (5.3)	498,518		
	No bipolar disorder (%)	Bipolar disorder (%)	Total (row-wise)	OR	z-score (p)
Normal thyroid function	477,574 (99.8)	778 (0.2)	478,352		
Hypothyroidism	18,711 (99.7)	52 (0.3)	18,763	1.99	4.74 (2.16×10 ⁻⁶)
Hyperthyroidism	1,402 (99.93)	1 (0.07)	1,403	0.457	-0.78 (0.434)
Total (column-wise)	497,687 (99.8)	831 (0.2)	498,518		
	No major depressive disorder (%)	Major depressive disorder (%)	Total (row-wise)	OR	z-score (p)
Normal thyroid function	312,767 (65.4)	165,585 (34.6)	478,352		

Hypothyroidism	9,817 (52.3)	8,946 (47.7)	18,763	1.51	27.09 ($<10^{-16}$)
Hyperthyroidism	805 (57.4)	598 (42.6)	1,403	1.24	3.86 (1.11×10^{-4})
Total (column-wise)	323,389 (64.9)	175,129 (35.1)	498,518		

Table 3. Global genetic correlation between thyroid hormone levels and thyroid diseases with affective disorders

	h2 SNP	Anxiety disorder r_g (p)	Major depressive disorder r_g (p)	Bipolar disorder r_g (p)
h2 SNP		0.08	0.07	0.35
Hypothyroidism	0.05	0.17 (2.2×10^{-4})	0.17 (8.5×10^{-5})	0.02 (0.52)
TSH normal range	0.11	0.05 (0.43)	-0.05 (0.37)	-0.04 (0.42)
TSH entire range	0.10	0.02 (0.67)	-0.03 (0.55)	-0.06 (0.12)
FT4 normal range	0.15	-0.02 (0.71)	-0.04 (0.36)	-0.03 (0.55)
Autoimmune thyroid disease	0.03	0.16 (6.7×10^{-6})	0.13 (2.7×10^{-4})	0.004 (0.89)

Table 4. Top local genetic correlations between autoimmune thyroiditis and anxiety disorder

Locus	Chr	start	stop	SNP count	PCs	Rho	p
952	6	27261036	28666364	316	41	0,87	$6,5 \times 10^{-6}$
1804	12	68839662	70097805	459	135	1	0,00011
951	6	26396201	27261035	202	32	0,72	0,00060
267	2	59251997	60775066	626	178	-0,67	0,00071
932	6	6621938	7808323	519	179	-0,81	0,00077
2072	15	69089816	70767983	486	166	0,80	0,0015
2453	21	39252060	40480831	511	175	-0,69	0,0021
861	5	10290398 6	103788460	271	89	-0,77	0,0032
1559	10	79952997	81190573	529	172	-0,61	0,0035
1215	7	13875510 8	140217630	325	117	-0,75	0,0057
2485	22	41722788	42867927	277	59	0,84	0,0065
1391	9	15839404	16658377	413	141	-0,70	0,0097
1671	11	60515106	61717117	269	94	0,71	0,012
226	2	22429641	23538527	315	102	-0,86	0,012
203	2	1376546	1875060	186	72	-0,72	0,013
1576	10	98005995	99367800	466	125	-0,75	0,014
2022	14	95946793	97174314	539	165	-1	0,016
1059	6	13145716 5	132890694	404	123	0,61	0,016
35	1	36855140	38474036	514	137	0,73	0,018

Table 5. Top local genetic correlations between autoimmune thyroiditis and major depressive disorder

locus	chr	start	stop	SNP count	PCs	Rho	p
951	6	26396201	27261035	294	42	0,77	2.7×10^{-6}
952	6	27261036	28666364	591	60	0,77	2.8×10^{-5}
961	6	31427210	32208901	221	61	0,51	0,00022
11	1	8580988	9475966	224	78	-1	0,00048
950	6	25684630	26396200	455	67	0,82	0,00089
960	6	31320269	31427209	19	15	0,55	0,0013
57	1	66778016	67761890	540	91	-1	0,0015
932	6	6621938	7808323	675	203	-0,82	0,0016
1301	8	64215359	66018204	531	108	0,70	0,0027
1804	12	68839662	70097805	581	152	0,92	0,0030
759	4	177129679	178314527	540	144	-0,74	0,0031
2336	19	29389091	30375792	416	115	-1	0,0035
332	2	141802665	142494980	378	88	1	0,0035
957	6	30715007	31106493	64	23	0,42	0,0038
966	6	32629240	32682213	2	2	1	0,0043
968	6	32897999	33194975	106	33	0,66	0,0054
478	3	65326752	66702084	514	170	-0,78	0,0071
1283	8	40974255	41725002	324	99	1	0,0079
2405	20	41351515	42185671	363	127	-0,92	0,0081

Supplementary Tables

Table S1. Thyroid disease definition based on ICD diagnosis codes

	ICD-10 codes	#Subjects
Hypothyroidism	E039	20,904
	E063	301
Hyperthyroidism	E050	681
	E052	140
	E059	2,105
Exclusion codes	C73, D34, D093, E051, E053, E054, E058, E060, E061, E062, E064, E065, E069, E030, E031, E032, E033, E034, E035, E038, E890	3,028

Table S2. Psychiatric disorder definition based on UK biobank data fields

Disorder	Field numbers	#Subjects
Anxiety disorder (ANX)	<p>Field 20544: mental health problems ever diagnosed by a professional (codes 1,5,6,15 and 17)</p> <ul style="list-style-type: none"> -Social anxiety or social phobia -Any other phobia (e.g., disabling fear of heights or spiders) -Panic attacks -Anxiety, nerves or generalized anxiety disorder -Agoraphobia -no comorbidity: schizophrenia, ADHD, ASD, BIP, Bulimia nervosa, psychological over-eating or binge-eating 	26,333
Major depressive disorder (MDD)	<p>Fields 2090 and 2100</p> <ul style="list-style-type: none"> -Seen doctor (GP) for nerves, anxiety, tension or depression -Seen a psychiatrist for nerves, anxiety, tension or depression <p>Field 41202: diagnoses - main ICD10</p> <ul style="list-style-type: none"> -F32: Depressive episode -F33: Recurrent depressive disorder -F34: Persistent mood [affective] disorders -F38: Other mood [affective] disorders -F39: Unspecified mood [affective] disorder 	175,129
Bipolar disorder (BIP)	<p>Field 20544: mental health problems ever diagnosed by a professional (code 10)</p> <ul style="list-style-type: none"> -Mania, hypomania, bipolar or manic-depression 	831